The WHO presentation reviewed the global status of HPV vaccine introduction, noting that 74% of countries have adopted HPV vaccination programs with increasing coverage driven by major introductions in Asia and Africa. It highlighted the 2022 recommendation for a single-dose schedule, now adopted by 58 countries, including high-income nations. Recent evidence supports the inclusion of Cecolin for single-dose use, alongside Cervarix and Gardasil vaccines, with Walrinvax newly prequalified. Supply constraints remain short-term, but projections indicate stable availability and broader catch-up strategies up to 20 years of age.